Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T lymphocytes Hu1928-Hu20BB

A preparation of autologous human T lymphocytes that have been genetically modified to express the CAR construct Hu1928-Hu20BB that consists of two chimeric antigen receptor (CAR) constructs: one encoding a fully-human anti-CD19 CAR with a co-stimulatory domain of CD28, Hu19-CD828, and one encoding a human anti-CD20 CAR with a co-stimulatory domain of 4-1BB (CD137), Hu20BB, with potential immunostimulating and antineoplastic activities. Upon re-infusion, the anti-CD19-CAR-CD28/CD20-CAR-4-1BB-expressing autologous T lymphocytes Hu1928-Hu20BB recognize and kill CD19- and/or CD20-expressing tumor B cells. This results in a cytotoxic T-lymphocyte (CTL) response against CD19- and/or CD20-expressing tumor cells, thereby causing tumor cell lysis. Both the tumor-associated antigens (TAAs) CD19 and CD20 are B-cell-specific cell surface antigens overexpressed in B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19/CD20 CAR autologous T lymphocytes Hu1928-Hu20BB
autologous CAR-19/CAR-20-T cells Hu1928-Hu20BB
Hu1928-Hu20BB
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search